ChromaDex Q1 revenue $22.6M (+31% YoY), net loss narrows to $1.9M, raises 2023 outlook

Niagen Bioscience, Inc.

2023-Q1 EPS reported -$0.03 revenue$22,556,000

Record Q1 net sales $22.6M (+31% YoY); Tru Niagen contributed $17.6M.
Gross margin 59.9%; SG&A as % of sales improved to 34.9% from 47.7%.
Net loss $1.9M ($0.03 EPS) vs $7.7M ($0.11 EPS) in Q1 2022; Adjusted EBITDA loss only $0.1M.
Raised conservative end of 2023 revenue outlook to 12.5% growth; generated $2.8M positive operating cash flow.
Operating expenses reduced $2.8M (-15%) driven by lower legal, share-based comp, and severance costs.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Niagen Bioscience, Inc. reported the three months ended March 31, 2023 results: revenue $22.6 million, net income $1.9 million, EPS $(0.03) per share.

Period: the three months ended March 31, 2023
Revenue: $22.6 million
Net income: $1.9 million
EPS: $(0.03) per share
Result: reported results

Exact text from the filing

ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-017206

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.